Sirolimus-eluting airway stent reduces profibrotic Th17 cells and inhibits laryngotracheal stenosis

Keyphrases

• Profibrotic 100%
• Sirolimus 100%
• T Helper 17 (Th17) 100%
• Airway Stent 100%
• Laryngotracheal Stenosis 100%
• Mammalian Target of Rapamycin (mTOR) 58%
• CD4+ T Cells 33%
• Pathologic 25%
• Fibrosis 25%
• Fibroblasts 16%
• CD4+ T 16%
• Clinical Treatment 8%
• Inflammation 8%
• Signaling Pathway 8%
• Trachea 8%
• Cell-mediated 8%
• CD4 Cells 8%
• Collagen Type 1 8%
• T-cell Phenotype 8%
• Stenosis Model 8%
• Drug-eluting Stent 8%
• Cell Phenotype 8%
• Hypermetabolic 8%
• Selective Deletion 8%
• Multispectral Immunofluorescence 8%

Medicine and Dentistry

• Rapamycin 100%
• Th17 Cell 100%
• Laryngotracheal Stenosis 100%
• T-Helper Cell 50%
• Mammalian Target of Rapamycin 33%
• Fibrosis 25%
• mTOR Signaling 25%
• Fibroblast 16%
• In Vitro 8%
• Immunofluorescence 8%
• T Cell 8%
• Signal Transduction 8%
• Trachea 8%
• Collagen Type 1 8%
• Larynx 8%
• Drug-Eluting Stent 8%

Immunology and Microbiology

• Sirolimus 100%
• Th17 Cell 100%
• T-Helper Cell 85%
• mTOR Signaling 42%
• Fibroblast 28%
• T Cell 14%
• Signal Transduction 14%
• CD4 14%
• Murine 14%
• Immunofluorescence 14%